- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
First-time generic approval
Mometasone topical solution 0.1% (equiv to Elocon topicallotion)
Mometasone topical solution 0.1% (equiv to Elocon topicallotion)
AIGIS INDUSTRIES
Octreotide injection 0.2 mg/mL (base) and 1 mg/mL (base) (equiv to Sandostatin injection)
BEDFORD
Fexofenadine/pseudoephedrine extended-release tablets 60/120 mg (equiv to Allegra D extended-release tablets)
BARR
Anagrelide capsules 0.5 mg (base) and 1 mg (base) (equiv to Agrylin capsules)
IMPAX, IVAX, ROXANE, WATSON, BARR, EON, MYLAN
Tramadol/acetaminophen tablets 37.5/325 mg (equiv to Ultracet tablets)
KALI LABORATORIES
Clozapine tablets 50 mg (equiv to Clozaril tablets)
IVAX
Doxycycline tablets 20 mg (equiv to Periostat tablets)
MUTUAL PHARMACEUTICAL COMPANY, IVAX, WEST-WARD
Fenofibrate tablets 54 and 160 mg (equiv to Tricor tablets)
TEVA
Ceftriaxone for injection 10 g/vial (pharmacy bulk package) (equiv to Rocephin for injection)
SANDOZ
Foscarnet injection 24 mg/mL, 250 and 500 mL bottles (equiv to Foscavir injection)
PHARMAFORCE
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
